Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

Provider Practices Regarding Prophylactic Anticoagulation in Children with Leukemia

Nicole Kucine, MD, Melanie Degliuomini, MD, Elizabeth Mauer, MS, Victoria Cooley, MS, Linda M Gerber, PhD, Suchitra Acharya, MD

Blood (2019) 134 (Supplement_1): 3412.

https://doi.org/10.1182/blood-2019-123084

Published: 2019

Journal Articles

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Pamela Allen, MD MSc, Hatice Savas, MD, Andrew M. Evens, DO,MSc, Barbara Pro, MD, Reem Karmali, MD, Brett Alan Palmer, BS, Eric Mou, MD, Jeffrey Bearden, BA, Denise M Scholtens, PhD, Gary Dillehay, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 235.

https://doi.org/10.1182/blood-2019-123906

Published: 2019

Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Blood (2019) 134 (Supplement_1): 236.

https://doi.org/10.1182/blood-2019-122406

Published: 2019

Journal Articles

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Eldad J Dann, MD, Rebeca Lopez-Alonso, Shunan Qi, Tania Mashiach, Michal Weiler-Sagie, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4051.

https://doi.org/10.1182/blood-2019-122824

Published: 2019

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

Ruetima Titapiwatanakun, MD, Sukhjeet Singh Batth, MD, Katherine Baker, NP, Wendy Tcheng, MD, Karen S. Fernandez, MD

Blood (2019) 134 (Supplement_1): 5298.

https://doi.org/10.1182/blood-2019-122973

Published: 2019

Journal Articles

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, Ni-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 5729.

https://doi.org/10.1182/blood-2019-131437

Published: 2019

Journal Articles

Using Childhood International Prognostic Scoring in Pediatric Hodgkin Lymphoma Patients Treated with ABVD Can Mitigate Use of Interim PET in LMIC

Reham Khedr, MD, Hanaa Rashad, MD, Asmaa Mohammed Hamoda, MD PhD MSc, Eman Khorshed, PhD, Madeha Elwakeel, PhD, Mohamed Saad, MD, Engy Mohamed, Emad Moussa

Blood (2019) 134 (Supplement_1): 1562.

https://doi.org/10.1182/blood-2019-132195

Published: 2019

Journal Articles

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Patrizia Mondello, MD PhD MSc, Irene Dogliotti, MD, Jan-Paul Bohn, Federica Cavallo, Simone Ferrero, MD, Barbara Botto, Claudio Cerchione, MD PhD, Davide Nappi, Sonya De Lorenzo, Giovanni Martinelli, MD, Dominik Wolf, Univ. Prof. Dr., Giacomo Loseto, MD, Salvatore Cuzzocrea, MD PhD, Wolfgang Willenbacher, MD PhD, Michael Mian, MD

Blood (2019) 134 (Supplement_1): 1565.

https://doi.org/10.1182/blood-2019-128198

Published: 2019

Journal Articles

Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas

Jakub Svoboda, MD, Steven M. Bair, MD, Christian Steidl, MD, Marco Ruella, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MD MRCP, MS, M. Reza Nejati, MD, James Nathan Gerson, MD, Lauren Elizabeth Strelec, BA, Matthew R. Youngman, BS, Elise A. Chong, MD, Olga Kutovaya, PhD, Stacy Hung, Agata M. Bogusz, MD PhD, Megan S. Lim, MD, PhD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 2959.

https://doi.org/10.1182/blood-2018-99-115024

Published: 2018

Journal Articles

Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience

Vasiliki Michalarea, MD, Dima El-Sharkawi, MBBS BSc FRCPath MD, Siraj Yusuf, Mary Gleeson, Laura Hickmott, Andrew Wotherspoon, Ayoma Attygalle, Simon O'Connor, Bhupinder Sharma, Yong Du, Imene Zerizer, Alan Horwich, Gillian Ross, Andrea Kuhnl, Sunil Iyengar, Ian Chau, MD, David Cunningham

Blood (2018) 132 (Supplement 1): 4240.

https://doi.org/10.1182/blood-2018-99-119560

Published: 2018

Journal Articles

Deficiency of Adenosine Deaminase 2 (DADA2) Presenting As Familial Hodgkin Lymphoma

Fahad Alabbas, Omar Alsharief, Isabelle Meyts, Fatma Albatniji, Michael Hershfield, Adnan Mansoor, MD PhD, Ghaleb Elyamany, MD PhD

Blood (2018) 132 (Supplement 1): 5373.

https://doi.org/10.1182/blood-2018-99-116431

Published: 2018

Journal Articles

Mediastinal Mass, Triglycerides Level Above 1000mg/Dl and Intensive Dexamethasone and Asparaginase Treatment Are Risk Factors for Cerebral Sinus Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon

Habib El-Khoury, B.Sc., MD Candidate, Khaled M Ghanem, MD, Yaacoub Mubarak, Nidale Tarek, MD, Hassan El Solh, Anthony K.C. Chan, MBBS, Carole Aridi, Miguel R. Abboud, Raya Saab, MD, Samar A. Muwakkit, MD

Blood (2018) 132 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2018-99-119638

Published: 2018

Journal Articles

Single Nucleotide Polymorphisms and Thromboembolism in Acute Lymphoblastic Leukemia — a NOPHO ALL2008 Study

Kirsten Brunsvig Jarvis, MD, Marissa Le Blanc, PhD, Morten Tulstrup, MD, Ellen Ruud, MD PhD Prof, Ruta Tuckuviene, MD PhD, Susanna Ranta, MD PhD, Kjeld Schmiegelow, MD DMSc

Blood (2018) 132 (Supplement 1): 143.

https://doi.org/10.1182/blood-2018-99-109902

Published: 2018

Journal Articles

Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years

Blood (2018) 131 (22): 2475–2484.

https://doi.org/10.1182/blood-2018-01-827949

Published: 2018

Includes: Supplemental data

Journal Articles

Thromboembolism in ALL Patients 1-45 Years Treated According to the NOPHO-ALL 2008 Protocol

Cecilie Rank, MD, Nina Toft, MD PhD, Ruta Tuckuviene, MD PhD, Kathrine Grell, PhD, Ove Juul Nielsen, MD DMSc, Thomas Leth Frandsen, MD PhD, Ulf Tedgaard, MD PhD, Helene Hallböök, MD PhD, Ellen Ruud, MD PhD, Petter Quist-Paulsen, MD PhD, Kaisa Vepsäläinen, MD, Ulla Wartiovaara-Kautto, MD PhD, Ólafur G. Jónsson, MD, Sonata Saulyte Trakymiene, MD, Laimonas Griškevičius, MD PhD, Kadri Saks, MD, Mari Punab, MD, Kjeld Schmiegelow, MD DMSc

Blood (2017) 130 (Supplement 1): 2564.

https://doi.org/10.1182/blood.V130.Suppl_1.2564.2564

Published: 2017

Journal Articles

Collaborative Risk-Adapted Treatment for Pediatric Acute Lymphoblastic Leukemia in Mexico

Pablo Gonzalez-Montalvo, MD, Hugo Romo, MD, Lourdes Vega-Vega, MD, Fernando Sanchez-Zubieta, MD, Eduardo Altamirano-Alvarez, MD, Rebeca Rivera-Gomez, MD, Maite Echavarria-Valenzuela, MD, Oscar Gonzalez-Ramella, MD, Daniela Covarrubias-Zapata, MD, Mónica Malavar-Guadarrama, MD, Paula Aristizabal, MD, Paola Friedrich, MD, Gaston K Rivera, MD, Carlos Rodriguez-Galindo, MD

Blood (2017) 130 (Supplement 1): 2116.

https://doi.org/10.1182/blood.V130.Suppl_1.2116.2116

Published: 2017

Journal Articles

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Blood (2017) 130 (Supplement 1): 736.

https://doi.org/10.1182/blood.V130.Suppl_1.736.736

Published: 2017

Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Blood (2017) 130 (Supplement 1): 737.

https://doi.org/10.1182/blood.V130.Suppl_1.737.737

Published: 2017

NARROW

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Provider Practices Regarding Prophylactic Anticoagulation in Children with Leukemia

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Using Childhood International Prognostic Scoring in Pediatric Hodgkin Lymphoma Patients Treated with ABVD Can Mitigate Use of Interim PET in LMIC

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas

Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience

Deficiency of Adenosine Deaminase 2 (DADA2) Presenting As Familial Hodgkin Lymphoma

Mediastinal Mass, Triglycerides Level Above 1000mg/Dl and Intensive Dexamethasone and Asparaginase Treatment Are Risk Factors for Cerebral Sinus Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon

Single Nucleotide Polymorphisms and Thromboembolism in Acute Lymphoblastic Leukemia — a NOPHO ALL2008 Study

Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years

Thromboembolism in ALL Patients 1-45 Years Treated According to the NOPHO-ALL 2008 Protocol

Collaborative Risk-Adapted Treatment for Pediatric Acute Lymphoblastic Leukemia in Mexico

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only